HWL-088

HWL-088 is a highly potent and orally active free fatty acid receptor 1 (FFA1/GPR40) agonist (EC50 of 18.9 nM) with moderate PPARδ activity (EC50 of 570.9 nM) . HWL-088 improves glucose and lipid metabolism, and has anti-diabetic effects[1][2].

Product Specifications

CAS Number

[2378617-96-8]

UNSPSC

12352005

Target

Free Fatty Acid Receptor; PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; GPCR/G Protein; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/hwl-088.html

Concentration

10mM

Purity

98.61

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

CC1=CC=CC=C1C2=CC(COC3=CC=C(OCC(O)=O)C(F)=C3)=CC=C2

Molecular Formula

C22H19FO4

Molecular Weight

366.38

References & Citations

[1]Li Z, et al. Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold. Bioorg Chem. 2019 Nov;92:103209.|[2]Yueming Chen, et al. HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice. Br J Pharmacol. 2020 May;177 (10) :2286-2302.